Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.80 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.73 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763498 | 0.91 | SYK (0.80) | SYKPDGFRBPDGFRASTAT6EGFR | |
| SCHEMBL763394 | 0.90 | SYK (0.87) | SYKPDGFRBPDGFRAEGFRFGFR1 | |
| SCHEMBL736542 | 0.89 | SYK (1.00) | SYKEGFRFGFR1 | |
| SCHEMBL764438 | 0.87 | SYK (0.79) | SYKPDGFRBPDGFRAEGFRFGFR1 | |
| SCHEMBL29793872 | 0.84 | PDGFRB (1.00) | SYKPDGFRBPDGFRAEGFRFGFR1 | |
| SCHEMBL26395469 | 0.84 | PDGFRB (1.00) | SYKPDGFRBPDGFRAEGFRFGFR1 | |
| SCHEMBL10242654 | 0.83 | SYK (0.73) | SYKPDGFRBPDGFRAEGFR | |
| SCHEMBL10241915 | 0.83 | SYK (0.73) | SYKPDGFRBPDGFRAEGFR | |
| SCHEMBL28638852 | 0.82 | EGFR (0.77) | SYKPDGFRBPDGFRAEGFRFGFR1 | |
| SCHEMBL764418 | 0.81 | SYK (0.67) | SYKPDGFRBPDGFRAEGFRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | SYK 1/4885PDGFRB 243/4885PDGFRA 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.